About Molecule
Molecule is a decentralized biotech protocol, building a web3 marketplace for research-related IP. Our platform and scalable framework for biotech DAOs connects academics and biotech companies with quick and easy funding, while enabling patient, researcher, and funder communities to directly govern and own research-related IP.
Our ecosystem

Scientists, engineers, lawyers, and operators building the future of biotech — alongside the contributors and advisors who shape our direction.

Protocol Architect
With a PhD in Nanotechnology and experience leading Web3 projects for global brands, Phill applies a rigorous, analytical approach to designing scalable decentralized systems. Driven by decentralized science’s potential to reshape innovation.

People & Talent Manager
People & Talent professional with a passion for building high-performing teams in web3 and deep tech. Committed to connecting top talent with mission-driven organisations to drive innovation and growth.
03 -- The pipeline
Once your Lab exists, it carries the project through every stage of commercializing your science.
Upload your data into an encrypted data room and bring in collaborators by email, each with the right level of access, so the work stays confidential while the team moves it forward.
Tokenize your research via the Molecule Protocol, turning research that was hard to value into something your community can fund and hold.
Open funding through tokens, while your public project page and activity feed connect the work and its data to the people backing it.
When the time is right, Coin-to-Company gives locked token holders a compliant path to real equity in the company behind the science.
“We're currently utilizing the Molecule platform and its IPT model to further fund our research. This revolutionary concept of IP fractionalization allows community involvement in the drug development process, creating a mutually beneficial situation. For us, it enables unlocking additional capital in a collaborative manner. For the community, it gives them an opportunity to directly support projects in a manner previously unavailable.”
Michael Torres - CEO of ArtanBio
